Thursday, October 06, 2016 9:17:21 PM
Synthetic Biologics produces therapies for infectious diseases that still protect the natural microbial balance in the gastrointestinal tract. One of its drugs in development is ribaxamase, code-named SYN-004, designed to prevent infections from Clostridium difficile or C. difficile bacteria. According to CDC, almost a half-million C. difficile infections occurred in the U.S. in 2011, leading to 29,000 deaths within 30 days of diagnosis.
C. difficile infections are often contracted in health care facilities, such as clinics and hospitals, causing inflammation in the colon, and symptoms including watery diarrhea, abdominal pain, nausea, loss of appetite, and fever. People who have other illnesses or conditions requiring prolonged use of antibiotics, and the elderly, are at greater risk of this disease.
SYN-004 is a synthetic enzyme formulated as an oral drug to degrade a common type of antibiotics, known as beta-lactam antibiotics, in the gastrointestinal tract. Beta-lactam antibiotics include widely used penicillins and cephalosporins, administered through intravenous infusions, which can pass into the gastrointestinal tract and kill helpful microbes, such as those that naturally protect against C. difficile infections. By degrading beta-lactam antibiotics, SYN-004 protects helpful microbes, thus preserving the body’s natural defenses against C. difficile.
The CDC grant funds a study by Synthetic Biologics to assess the way pressure from intravenous antibiotics encourages the emergence of antibiotic resistance in gut microbial communities. The company plans to extract DNA samples from participants enrolled in an intermediate-stage clinical trial testing SYN-004 against a placebo to prevent C. difficile infections. The trial is enrolling patients receiving ceftriaxone, a type of beta-lactam antibiotic, administered intravenously, for lower respiratory infections. The study team will look for changes in the presence and number of genes associated with antibiotic resistance in those DNA samples.
Synthetic Biologics is the only grant recipient from industry in the initiative, with the other investigators coming from universities and OpenBiome, a not-for-profit organization. OpenBiome operates a stool bank that collects fecal samples for research and transplants, a treatment option for C. difficile infections.
Recent TOVX News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/18/2024 09:06:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:10:34 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/11/2024 12:45:02 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/10/2024 09:03:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 09:11:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 12:22:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:21:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 12:16:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:05:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 12:20:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:20:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 11:30:14 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:10:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:05:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:10:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:07:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:01:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:15:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 11:10:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 10:05:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 10:06:35 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM